Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Opthea Limited ( (AU:OPT) ) has shared an announcement.
Opthea Limited announced that data regarding their lead product, sozinibercept, will be featured at the Macula Society 48th Annual Meeting. The presented Phase 2b study data indicates that sozinibercept 2 mg combination therapy provides superior vision and anatomical outcomes for wet AMD compared to standard ranibizumab treatment, with specific angiographic lesion characteristics predicting patient response. This development underscores sozinibercept’s potential to significantly enhance treatment for wet AMD, possibly becoming the first new effective therapy in two decades, which could influence Opthea’s position in the retinal disease treatment market and impact stakeholders positively.
More about Opthea Limited
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening eye diseases, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor, is currently in Phase 3 development and aims to improve vision outcomes when used in combination with standard anti-VEGF-A therapies.
YTD Price Performance: 9.09%
Average Trading Volume: 9,900
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $831.6M
For detailed information about OPT stock, go to TipRanks’ Stock Analysis page.
